Myllia Biotechnology GmbH
- Biotech or pharma, therapeutic R&D
- Other products or services
- Other R&D services
Myllia performs CRISPR screens for biotech and pharma clients. We perturb primary human cells and cancer cell lines with CRISPRn, CRISPRi or CRISPRa and combine it with various read-outs such as fitness, FACS, CITE-Seq or scRNA-Seq. Our CRISPR-based functional genomics platform enables drug target identification/validation in primary cellular models that ultimately translate to human disease biology.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}